Drugs / PFK-158
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02044861 | Mar 2014 → Sep 2015 | cancer | Advanced Cancer Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PFK-158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02044861 ↗ |
| Action | Inhibit | “ACT-PFK-158 is a novel anti-cancer agent that inhibits glucose uptake in cancer cells.” NCT02044861 ↗ |
| Modality | Small molecule | — CHEMBL4303611 ↗ |
| Route | Intravenous | “IV dose escalation” NCT02044861 ↗ |